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isoform regulates IL-17A levels and mechanical
allodynia after peripheral nerve injury
Huaqing Liu1,2, Jennifer Dolkas1,2, Khan Hoang1,2, Mila Angert1,2, Andrei V. Chernov3, Albert G. Remacle3,
Sergey A. Shiryaev3, Alex Y. Strongin3, Tasuku Nishihara1,2 and Veronica I. Shubayev1,2*Abstract
Background: Mechanical pain hypersensitivity associated with physical trauma to peripheral nerve depends on
T-helper (Th) cells expressing the algesic cytokine, interleukin (IL)-17A. Fibronectin (FN) isoform alternatively spliced
within the IIICS region encoding the 25-residue-long connecting segment 1 (CS1) regulates T cell recruitment to
the sites of inflammation. Herein, we analyzed the role of CS1-containing FN (FN-CS1) in IL-17A expression and pain
after peripheral nerve damage.
Methods: Mass spectrometry, immunoblotting, and FN-CS1-specific immunofluorescence analyses were employed
to examine FN expression after chronic constriction injury (CCI) in rat sciatic nerves. The acute
intra-sciatic nerve injection of the synthetic CS1 peptide (a competitive inhibitor of the FN-CS1/α4 integrin binding)
was used to elucidate the functional significance of FN-CS1 in mechanical and thermal pain hypersensitivity and
IL-17A expression (by quantitative Taqman RT-PCR) after CCI. The CS1 peptide effects were analyzed in cultured
primary Schwann cells, the major source of FN-CS1 in CCI nerves.
Results: Following CCI, FN expression in sciatic nerve increased with the dominant FN-CS1 deposition in
endothelial cells, Schwann cells, and macrophages. Acute CS1 therapy attenuated mechanical allodynia (pain from
innocuous stimulation) but not thermal hyperalgesia and reduced the levels of IL-17A expression in the injured
nerve. CS1 peptide inhibited the LPS- or starvation-stimulated activation of the stress ERK/MAPK pathway in
cultured Schwann cells.
Conclusions: After physical trauma to the peripheral nerve, FN-CS1 contributes to mechanical pain hypersensitivity
by increasing the number of IL-17A-expressing (presumably, Th17) cells. CS1 peptide therapy can be developed for
pharmacological control of neuropathic pain.
Keywords: Fibronectin, CS1, IL-17, Neuropathic, Pain, Allodynia, T cell, Th17, A-afferent, Myelin, Schwann cellIntroduction
Neuropathic pain, a severe pain state arising from a lesion
or disease of the nervous system, is refractory to analgesics
[1]. A rodent model of chronic constriction injury (CCI)
to the sciatic nerve allows to study the two major neuro-
pathic pain phenotypes of exaggerated pain from noxious
thermal stimulus (thermal hyperalgesia) and pain evoked* Correspondence: vshubayev@ucsd.edu
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Current understanding of the neuropathic pain mecha-
nisms recognizes the hyperalgesic activity of inflammatory
cytokines and chemokines, produced initially by the
resident cells of the nerve, including Schwann cells,
macrophages, and endothelial cells. These inflammatory
mediators contribute to both the depolarization of
nociceptors and the chemotactic gradients that guide
hematogenous monocytes and leukocytes into the dam-
aged nerve [2–8]. Sustained activity of the innate immune
system subsequently activates antigen-specific adaptive
immunity, which engages T helper (Th)1 and Th17 cellsdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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and IL-17A, respectively, to sustain neuropathic pain
states that follow nerve trauma [4, 9–17]. Conversely, Th2
and Treg(ulatory) cells express anti-inflammatory/anal-
gesic cytokines and traffic to the injury site in order to re-
duce pain [4, 9–17].
Differential regulation of mechanical but not thermal
(heat) hypersensitivity involves adaptive immunity mod-
ulators, such as IL-17A [13], IL-4 [18], toll-like receptor
4 [19], myelin basic protein [17], and fibronectin (FN)
[20], and engages low-threshold mechanosensory mye-
linated A-afferents [21, 22]. In contrast, inflammatory
modulators universally expressed by various immune
and glial cells, including TNF-α, IL-1β, and IL-6, indis-
criminately modulate thermal and mechanical pain
hypersensitivity [2–8] by stimulating heat-nociceptive C-
afferents and mechanosensitive A-afferents, respectively
[23, 24]. According to our recent findings, the proteoly-
sis of the insulating myelin sheath of A-afferents results
in the release of the cryptic myelin auto-antigens, which
stimulate the development of mechanical allodynia in
part via Th17 cell homing to myelinated fibers [17]. The
molecular events underlying Th17 cell homing in the
injured nerve and their emerging functions in nocicep-
tive circuits remain obscure.
T cells gain access into the sites of inflammation
via the integrin α4β1 binding to the connecting
segment 1 (CS1) isoform of FN. This isoform is alter-
natively spliced within the IIICS [or variable (V)] region
encoding the 25-residue-long CS1 peptide sequence
(Asp-Glu-Leu-Pro-Gln-Leu-Val-Thr-Leu-Pro-His-Pro-
Asn-Leu-His-Gly-Pro-Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr)
[25–28]. FN is an adhesion glycoprotein and a compo-
nent of the extracellular matrix that, among its multiple
functions, provides architectural scaffolding to regener-
ating axons [29, 30]. Alternative splicing of the EIIIA,
EIIIB, and IIICS exons of the FN gene in nerves leads to
the presence of the multiple FN isoforms [31, 32]. Re-
gardless of the abundance of the CS1-containing FN
(FN-CS1) isoform in the peripheral nerve and cultured
Schwann cells [31, 32], the pathophysiological role of
FN-CS1 in T cell recruitment post-nerve injury is not
well understood. Typically, interference with the FN-
CS1 binding to the α4β1 integrin using the competitively
blocking CS1 peptide abrogates T cell homing to in-
flamed tissues [26, 28, 33, 34].
Herein, we have established that FN-CS1 controls the
content of IL-17A expressing (presumably Th17) cells
and mechanical allodynia in rats undergoing CCI. Con-
versely, acute therapeutic intervention that employs the
synthetic CS1 peptide attenuates mechanical allodynia,
presenting a likely valuable strategy to control the algesic
IL-17A action and mechanical pain hypersensitivity
phenotype associated with nerve trauma.Materials and methods
Animal model
All animal procedures were performed according to the
PHS Policy on Humane Care and Use of Laboratory
Animals and the protocols approved by the Institutional
Animal Care and Use Committee at the VA San Diego
Healthcare System and complied with ethical guidelines of
the International Association for the Study of Pain. Female
Sprague-Dawley rats (n = 53, 200–225 g, Harlan Labs)
were housed in a temperature-controlled room (at 22 °C)
on a 12-h light/dark cycle with free access to food and
water. Animals were anesthetized with 4 % isoflurane
(Aerrane; Baxter) in 55 % oxygen. The common sciatic
nerve was exposed unilaterally and received three loosely
constrictive chromic gut ligatures to produce CCI [35].
Naïve animals were used for control. All animals were
sacrificed using Beuthanasia i.p. (Schering-Plough Animal
Health), and sciatic nerve segments were collected for
analyses.
CS1 peptide therapy
The N-end acetylated and C-end amidated wild-type
CS1 (DELPQLVTLPHPNLHGPEILDVPST) and scram-
bled CS1 (sCS1, EPDELQTGHVLSPLNHTPVLIPLDP)
peptides were synthesized by GenScript. Immediately
after CCI, CS1 and sCS1 (50 μg/ml in 5 μl PBS) or PBS
alone (5 μl) were injected into the nerve fascicle (injury
site) using a Hamilton syringe with a 33-gauge needle.
Pain-like behaviors
Animals were habituated to the testing environment
prior to baseline tests. For assessment of mechanical
hypersensitivity, rats were placed in individual plexiglass
compartments with wire mesh bottom, and after
acclimatization, von Frey filaments (0.41–15.2 g, Stoelt-
ing) were applied perpendicularly to the mid hind paw
and held for 4–6 s. A positive response was noted if the
paw was sharply withdrawn. The 50 % probability of
withdrawal threshold was determined by Dixon’s up-down
method [36]. To assess thermal hypersensitivity, a modi-
fied Hargreaves-type device was employed [37]. Rats were
placed individually in plexiglass cubicles with a glass
surface, and after habituation, a radiant heat stimulus was
applied to each paw, and the latency defined as the time
(seconds) required for the paw to show a brisk withdrawal.
Tests were performed for 3 days before CCI and then at
days 1, 2, 3, 5, and 7 after CCI and therapy by an examiner
blinded to the experimental groups.
Neuropathology
Sciatic nerve segments were excised and post-fixed for
48 h at 4 °C using 2.5 % glutaraldehyde in 0.1 M phos-
phate buffer, pH 7.4. Specimens were washed using
phosphate buffer, post-fixed with 1 % osmic acid (Ted
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and propylene oxide, and embedded in Araldite resin
(Ted Pella). One-micron-thick sections were cut using a
diamond knife in an automated RM2065 microtome
(Leica Microsystems) and stained using methylene blue/
azure II solution [38]. Sections from three animals per
group and three randomly selected areas per section
were analyzed.
Immunofluorescence
Sciatic nerve segments were excised, post-fixed in 4 %
p-formaldehyde, cryoprotected in a 15–30 % sucrose
gradient, embedded into the optimal cutting temperature
(OCT) compound (Sakura Finetek) in liquid nitrogen, and
cut into 10-μm-thick transverse sections. Non-specific
binding was blocked using 10 % normal goat serum.
The slides were incubated for 16–18 h at 4 °C with
mouse anti-human CS1 antibody (EMD Millipore,
cat. #MAB1939), followed by incubation for 16–18 h
at 4 °C with Alexa Fluor 594-conjugated goat anti-mouse
IgM (Life Technologies, cat. #A21042). For dual immuno-
fluorescence, following the washes in PBS-1 % Tween, the
slides were incubated for 1–2 h at ambient temperature
with rabbit polyclonal CD68 antibody (Santa Cruz, cat.
#SC9139), followed by incubation with goat anti-rabbit
Alexa 488-conjugated secondary antibody (green, 1–2 h,
ambient temperature).
Teased nerve fibers were prepared from the separated
nerve bundles using fine smooth microforceps and incu-
bated in PBS-5 % fish skin gelatin-0.1 % Triton X-100 for
1 h. After the staining described above, individual fibers
were teased out on a glass slide using a 0.20- to 0.22-mm
acupuncture needle (Vinco, Oxford Medical Supplies) for
the follow-up observation. Slides were mounted using the
Slowfade Gold antifade reagent containing 4′,6-diamidino-
2-phenylindole (DAPI; Molecular Probes). Signal specificity
was confirmed by omitting the primary antibody. The im-
ages were acquired using a Leica DMRB microscope and
Openlab 4.04 software (Improvision).
Immunoblotting
Sciatic nerve and Schwann cell extracts were prepared
using 50 mM Tris-HCl, pH 7.4, containing 1 % Triton
X-100, 150 mM NaCl, 10 % glycerol, 0.1 % SDS, 5 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, aprotinin,
and leupeptin (1 μg/ml each). The protein concentration
of the extracts was determined using bicinchoninic acid
assay. Following reduction, aliquots of tissue and cell
extracts (40 μg and 10–15 μg each, respectively) were
separated by SDS-PAGE in a 5–12 % gradient gel.
Proteins were transferred onto a nitrocellulose support
using an iBlot dry blotting system (Invitrogen) at 20 V
for 7 min. The membranes were blocked using TBS-
0.1 % Tween-20–5 % non-fat milk (Bio-Rad) andincubated overnight at 4 °C with mouse FN antibody
(Santa Cruz, cat. #SC8422), rabbit phospho-ERK1/2 anti-
body (Thr202/Tyr204, Cell Signaling, cat. #9101), or
rabbit ERK1/2 antibody (Cell Signaling, cat. #9102)
followed by incubation for 1 h at ambient temperature
with horseradish peroxidase-conjugated goat anti-mouse
or anti-rabbit secondary antibodies (Cell Signaling). The
blots were developed using an enhanced chemilumines-
cence system (GE Healthcare). For loading control, the
membranes were re-probed using mouse β-actin anti-
body (Sigma, cat. #A53166). The band density was
measured in n = 3/group relative to that of β-actin using
Image J Software.qRT-PCR
Sciatic nerves were isolated and stored at −20 °C in RNA-
later (Ambion). Primers and Taqman probes for IL-17А
(GenBank #NM_001106897) were obtained from Applied
Biosystems (Assay ID Rn01757168_m1) and for glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH, GenBank
#X02231) from Biosearch Technologies [17]. Total cell
RNA was extracted using TRIzol (Invitrogen) and purified
using an RNeasy mini column (Qiagen). The RNA purity
was estimated by measuring the OD260/280 ratio. The
samples were treated with RNase-free DNAse I (Qiagen).
cDNA was synthesized using a SuperScript first-strand
RT-PCR kit (Invitrogen). Gene expression was measured
using a Mx4000™ Multiplex Quantitative PCR System
(Agilent Technologies) with 50 ng cDNA and 2× Taqman
Universal PCR Master Mix (Ambion). A one-step amplifi-
cation program (95 °C, 10 min; 95 °C, 30 s; 60 °C, 1 min)
was normally used for 50 cycles. For naïve nerve samples
that do not exhibit any IL-17A signal, a threshold cycle
(Ct) value of 51 was assigned to allow calculations.
Duplicate samples missing cDNA (a “no template” con-
trol) showed no contaminating DNA. Relative mRNA
levels were quantified using the 2(-Delta Delta C(T))
method [39]. Normalization to GAPDH and fold-change
calculations were performed using MxPro software (Agilent
Technologies).Two-dimensional liquid chromatography/tandem mass
spectrometry/mass spectrometry (2D-LC/MS/MS)
Sciatic nerves were isolated, snap-frozen in liquid nitro-
gen, and stored at −80 °C. The samples were homoge-
nized, sonicated, and extracted 60 min at ambient
temperature in 100 mM Tris-HCl, pH 8.0, containing
8 M urea and the protease and phosphatase inhibitor
cocktail. The insoluble material was removed by centri-
fugation (16,000×g; 15 min). The supernatant samples
(at least 0.5 mg total protein each) were then processed
by the Proteomics Core facility of the Sanford-Burnham
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(10 mM tris(2-carboxyethyl) phosphine, 37 °C, 30 min),
alkylated (20 mM iodoacetamide, 37 °C, 40 min in the
dark), and digested using modified trypsin, mass spectrom-
etry grade (Promega; 1:100 w/w ratio; 37 °C, 16–18 h). The
samples were desalted using a SepPack cartridge, dried
using a SpeedVac, and re-suspended in 0.1 ml 5 % formic
acid. The resulting peptides were separated into 24 frac-
tions using an offline Michrom MDLC pump (Michrom)
with a Michrom Strong Cation Exchange column. The 1/
10 aliquot of each peptide fraction was analyzed using an
LTQ-Orbitrap XL mass-spectrometer (Thermo Scientific)
and a 15-cm Michrom Magic C18 column coupled with a
low-flow Michrom ADVANCED device. The data were
analyzed by Sorcerer Enterprise v.3.5 software (Sage-N
Research) using the ipi.Rat.v3.56 protein database. To
identify carboxyamidomethylated cysteines, 57 Da were
added to cysteines, and 16 Da were added to methionines
to identify oxidated methionines. The search results were
sorted, filtered, and statistically analyzed using a trans-
proteomic pipeline (TPP) (Institute for Systems Biology)
with a 90 % minimum probability score and an error
rate ≤2 %. An additional, confirmatory search was per-
formed using a Prolucid search algorithm with a DTASelect
function via an Integrated Proteomics Pipeline (IP2) server.
Stimulation of cultured Schwann cells
Primary Schwann cell cultures were obtained using the
Brockes method [40]. Sciatic nerves of postnatal day 1–3
Sprague-Dawley rats (Harlan Labs) were isolated and
purified using AraC, an anti-fibronectin Thy1.1 antibody
and the rabbit complement [38, 41]. The purity of the
obtained cultures was confirmed by the Schwann-cell-
specific S100B immunopositivity (>99 %). Schwann cells
were re-suspended and plated in poly-D-lysine-coated
dishes in Dulbecco’s modified Eagles medium (DMEM),
containing 10 % fetal bovine serum (FBS), 100 units/ml
penicillin and 100 μg/ml streptomycin, 21 μg/ml bovine
pituitary extract, and 4 μM forskolin (referred to as
“complete medium”) at 37 °C under humidified 5.0 %
CO2. Cells of passage 3–7 were grown in a 6-well-dish
in a complete medium until reaching 70 % confluence.
Cells were then starved in DMEM-1 % FBS for 24 h and
treated with lipopolysaccharide (LPS; 100 ng/ml) from
Escherichia coli (Sigma, cat. # L2880) for 15 min at
37 °C. CS1 (2.5 μg/ml) was added into the medium, and
cells were incubated at 37 °C. In 15–60 min, cells were
washed twice at 37 °C using pre-warmed TBS. Cell
extracts were prepared using TBS supplemented with
1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 %
SDS, protease inhibitor cocktail, and 1 mM sodium
orthovanadate. The prepared extracts were subjected to
immunoblotting. Data was obtained from three inde-
pendent experiments.Data analyses
Statistical analyses were performed using KaleidaGraph
4.03 (Synergy Software) and InStat 3 (GraphPad Software)
using two-tailed, unpaired Student’s t-test for comparing
two groups or analyses of variance (ANOVA) for repeated
measures for comparing three or more groups, followed
by Tukey-Kramer post hoc test. p ≤ 0.05 values were
considered significant.
Results
FN-CS1 expression in CCI nerve
As schematically illustrated in Fig. 1a, FN is a dimer of
the 220–250-kDa nearly identical monomers linked via
disulfide bonds and encoded by a single FN transcript
[30]. The FN transcript undergoes alternative splicing
within the three independent exons, EIIA, EIIIB, and
IIICS (also known as variable, V) [42]. The V site pro-
duces no inserts (called V0) or two inserts of 95 or 120
amino acids (called V95 and V120, respectively, Fig. 1a)
differing by a 25-amino-acid CS1 segment [42]. In agree-
ment, the dominant 220-kDa band of the FN monomer
and additional species with the molecular weight over
250 kDa were observed in the normal nerve (Fig. 1b, c).
Concomitantly, the levels of the 220-kDa FN slightly
decreased while alternatively spliced FN species with the
molecular weight over 250 kDa were elevated at day 1
and especially day 7 post-CCI (p < 0.05), during T cell
recruitment [9–12].
To support these observations, the protein extracts
obtained from the CCI and sham-operated sciatic
nerves were subjected to 2D-LC/MS mass spectrom-
etry analysis. For these purposes, extracted proteins
were fully denatured, reduced, alkylated, and digested
by trypsin. The resulting trypsin fragments of the
nerve proteome were separated by liquid chromatog-
raphy (LC), and each fraction was next analyzed using
a mass spectrometer to determine the identity of the
peptides. Our in-detail analysis unambiguously identi-
fied a number of the FN peptides in the nerve samples
(Table 1). The length of the identified peptides if com-
bined represented 35 % of the FN protein sequence
(35 % coverage). Because of both the limited difference
in the expression levels of the FN isoforms in the in-
jured versus intact nerve [31, 32, 43] and the incom-
plete, albeit sufficient, coverage of the FN sequence,
the detected peptides are grouped together. The pres-
ence of the TDELPQLVTLPHPNLHGPEILDVPSTVQK
2081–2109 peptide that included the CS1 sequence
(italicized; the LDV sequence that is essential for the
binding to α4β1 integrin is in bold) implied that the
2477-residue-long rat FN-CS1 splice variant was
present in CCI nerve.
Using a specific antibody against the human FN-CS1
region (MAB1939, EMD Millipore), shown to cross-
Fig. 1 FN in CCI nerve. a Fibronectin (FN) exists as a heterodimer linked by disulfide bonds. One of the monomers includes the 25-amino-acid-long
CS1 sequence. Typical CS1 inclusion and exclusion splice variants are illustrated. b FN immunoblot of rat sciatic nerve, normal or at days 1 and 7 after
CCI. β-actin, a loading control (40 μg total protein). c The graph represents the mean levels of the individual FN isoform recorded in (b). ±SEM relative
to β-actin (n = 3–4/group; *p < 0.05, **p < 0.01, n.s. not significant). d FN-CS1 immunostaining (red) in sciatic nerves at day 7 post-CCI. The vessel (V)
endothelial cells, Schwann cells, and macrophages (confirmed using the CD68 immunostaining, green) are stained. DAPI, blue. Representative of
n = 3/group; scale bars, 40 μm. e FN-CS1 immunostaining (red) in a teased nerve fiber at day 7 post-CCI; representative of ~20 individual fibers from
n = 3. Scale bar, 10 μm. NoR node of Ranvier
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CS1 immunoreactivity in the sciatic nerve at day 7 post-
CCI (Fig. 1d). Consistent with the previous reports [30],
Schwann cells were the dominant source of FN-CS1. In
addition, FN-CS1 was produced by vessel endothelial
cells and CD68+ macrophages, which infiltrate sciatic
nerve between 2 and 14 days post-injury [8]. Because
Schwann cells deposit FN into the basement membrane
[30] and Fig. 1d, single nerve fibers were teased out and
immunostained for FN-CS1 at day 7 post-CCI for the
subsequent detailed analyses (Fig. 1e). Consistent with
the findings using pan-FN antibodies [30], the FN-CS1
immunoreactivity was dominant in the Schwann cellbasement membrane of myelinated fibers, including the
area immediately outside of the nodes of Ranvier.
Acute CS1 therapy attenuates mechanical allodynia and
IL-17A levels after CCI
Competitive inhibition of the FN-CS1 binding to integrin
α4 using a synthetic 25-residue-long CS1 peptide abrogated
T cell trafficking into inflamed tissues [26, 28, 33, 34],
required for the development of neuropathic pain pheno-
types [44]. To analyze the effect of CS1 peptide therapy on
pain-like behaviors, the wild-type CS1 peptide
(DELPQLVTLPHPNLHGPEILDVPST) or the scrambled
sCS1 peptide (EPDELQTGHVLSPLNHTPVLIPLDP)
Table 1 FN peptide sequences in the rat sciatic nerve
Peptide sequence Peptide sequence
1 69TYLGNALVCTCYGGSR84 27 1446TGLDSPTGFDSSDVTANSFTVHWVAPR1472
2 85GFNCESKPEPEETCFDK101 28 1473APITGYIIR1481
3 85GFNCESKPEPEETCFDKYTGNTYK108 29 1525EESPPLIGQQSTVSDVPR1542
4 118DSMIWDCTCIGAGR131 30 1570ITYGETGGNSPVQEFTVPGSK1590
5 118DSMIWDCTCIGAGRGRISCTIANR141 31 1591STATINNIKPGADYTITLYAVTGR1614
6 254GNLLQCVCTGNGR266 32 1615GDSPASSKPVSINYQTEIDKPSQMQVTDVQDNSISVR1651
7 274HVLQSASAGSGSFTDVR290 33 1652WLPSTSPVTGYR1663
8 291TAIYQPQTHPQPAPYGHCVTDSGVVYSVGMQWLK324 34 1708NGESQPLVQTAVTNIDRPK1726
9 370TFYSCTTEGR379 35 1727GLAFTDVDVDSIK1739
10 380QDGHLWCSTTSNYEQDQK397 36 1820FTQVSPTTLTAQWTAPSVK1838
11 398YSFCTDHAVLVQTR411 37 1857EINLSPDSTSVIVSGLM[147]VATK1877
12 458FGFCPMAAHEEICTTNEGVMYR479 38 1878YEVSVYALK1886
13 504GQWACIPYSQLR515 39 1887DTLTSRPAQGVVTTLENVSPPR1908
14 670GLTPGVIYEGQLISIQQYGHQEVTR694 40 1887DTLTSRPAQGVVTTLENVSPPRR1909
15 785YIVNVYQISEEGK797 41 1926TKTETITGFQVDAIPANGQTPVQR1949
16 798QSLILSTSQTTAPDAPPDPTVDQVDDTSIVVR829 42 1928TETITGFQVDAIPANGQTPVQR1949
17 821TQVSPTTLTAQWTAPSVK838 43 1957SYTITGLQPGTDYK1970
18 830WSRPQAPITGYR841 44 1982SSPVVIDASTAIDAPSNLR2000
19 881AVEENQESTPVFIQQETTGVPR902 45 2001FLTTTPNSLLVSWQAPR2017
20 911DLQFVEVTDVK921 46 2008SLLVSWQAPR2017
21 938VDVLPVNLPGEHGQR952 47 2081TDELPQLVTLPHPNLHGPEILDVPSTVQK2109
22 1011TVLVTWTPPR1020 48 2161LRPRPYLPNVDEEVQIGHVPR2181
23 1054NLQPGSEYTVTLMAVK1069 49 2165PYLPNVDEEVQIGHVPR2181
24 1116LGVRPSQGGEAPR1128 50 2255GVTYNIIVEALHNQR2269
25 1254ESAPISDTVIPEVPQLTDLSFVDITDSSIGLR1285 51 2321LTCQCLGFGSGHFR2334
26 1365FTNIGPDTMR1374 52 2401EYLGAICSCTCFGGQR2416
27 1446TGLDSPTGFDSSDVTANSFTVHWVAPR1472 53 2452TNTNVNCPIECFMPLDVQADRDDSRE2477
2D-LC-MS/MS of sciatic nerve samples was performed at day 7 after sham surgery or CCI. The sequence of the 53 identified FN peptides (with the total coverage
over 35 %) is shown. The presence of the TDELPQLVTLPHPNLHGPEILDVPSTVQK 2081–2109 peptide (#47) that included the CS1 sequence (italicized) implied that
the 2477 residue long rat FN-CS1 splice variant (GeneBank #P04937.2) was present in our nerve samples
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intra-sciatic bolus injection in the CCI injury site, immedi-
ately after CCI surgery. Mechanical and heat sensitivity of
the hind paw were then assessed once daily for one week
(Fig. 2). A characteristic drop in the mechanical withdrawal
threshold corresponding to robust mechanical allodynia
occurred after CCI in animals receiving either sCS1 or PBS
(Fig. 2a). In contrast, CS1 elevated the withdrawal thresh-
old in response to mechanical stimulation compared with
sCS1 or PBS. Neither CS1 nor sCS1 affected thermal
hyperalgesia developed after CCI (Fig. 2b). Based on our re-
sults, we concluded that acute local CS1 peptide therapy
delayed the development of mechanical, but not thermal,
pain hypersensitivity by at least 1 week.
IL-17, a Th17 cell cytokine in CCI nerves [10, 13],
selectively controls mechanical (but not thermal) pain
hypersensitivity [13]. Given these comparable effects ofthe CS1 therapy and IL-17 gene deletion [13], we tested a
model in which CS1 therapy acts by reducing IL-17A gene
expression in the CCI nerves. Following the behavioral
testing, we employed Taqman qRT-PCR to measure the
IL-17A mRNA levels (Fig. 3a) and ultrastructural analysis
(Fig. 3b) of the nerves exposed to CS1 or sCS1 peptides.
The IL-17A mRNA was undetectable in naïve nerve
(Fig. 3a), consistent with the report by others [10].
Accordingly, control nerve displayed the uniform morph-
ology of intact axons (Fig. 3b). The IL-17A levels were
significantly elevated in the injured nerves at day 7 post-
CCI in the rats that received sCS1 (Fig. 3a). These nerves
exhibited the characteristic features of Wallerian degener-
ation, including endoneurial edema, axon degeneration,
the presence of myelin ovoids, and immune cell clusters
(Fig. 3b). Both the IL-17A expression (Fig. 3a) and the
features of degeneration (Fig. 3b) were significantly
Fig. 2 Acute CS1 therapy attenuates mechanical allodynia. The CS1 and scrambled (sCS1) peptides each dissolved in PBS (50 μg/ml in 5 μl) or
PBS alone (5 μl) were administered by a single intraneural injection immediately after CCI (arrow). a von Frey testing for mechanical allodynia.
Decline in the withdrawal threshold in the ipsilateral (ipsi) to CCI hind paw treated with PBS represents allodynia sustained for the study duration.
sCS1 produced no significant change in the thresholds compared to PBS. In contrast, CS1-treated rats developed reduced sensitivity to tactile
stimuli, compared to sCS1 (#) and PBS (*). Contralateral to injury, hind paws displayed no sensitivity to stimulus in either treatment group. The
mean withdrawal thresholds (gram force; g) ± SEM of n = 6–17/group (* and #, p < 0.05, by ANOVA and Tukey’s post hoc test). b Hargreaves
testing for thermal sensitivity. Withdrawal latency to thermal stimulation (radiant heat) decreased after CCI compared with prior to CCI (baseline).
At the indicated days after CS1 and PBS injections, the sensitivity to thermal stimulation was not different between the groups. The mean paw
withdrawal latency (seconds; s) ± SEM of n = 6/group
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suggested that acute CS1 therapy decreased a number of
IL-17A+ (presumably, Th17) cells in the rodent neur-
opathy model.
CS1 reduces ERK/MAPK activation in Schwann cells
Since Schwann cells are the dominant cell type expressing
FN-CS1 post-CCI (Fig. 1), we evaluated the effect of CS1
peptide on Schwann cell activation (Fig. 4). Activation of
the extracellular-signal-regulated kinase (ERK)/mitogen-ac-
tivated protein kinase (MAPK) stress pathway contributes
to neuropathic pain [8, 44] and can be stimulated in
cultured primary Schwann cells by LPS treatment or low-
serum medium (LSM) starvation [45]. CS1 inhibited the
LPS- or starvation-stimulated activation of ERK (Fig. 4a). In
addition, a short 15- to 60-min co-incubation of the CS1
peptide with the cells decreased pERK1/2 activation in
Schwann cells that were stimulated with LPS for 15 min
prior to CS1 (Fig. 4b). Based on these data, we argued that
an intervention in the FN-CS1/α4β1 integrin interactions
using the CS1 peptide reduced Schwann cell activation
caused by stressful stimuli and or inflammation.
Discussion
The mechanisms underlying chronic low-threshold pain
phenotypes are poorly understood. Recent knowledge
recognizes the involvement of adaptive immune response
to physical nerve trauma, and specifically of Th cells, in
chronic pain pathophysiology [4, 9–17]. It is interesting to
note that adaptive immune cell modulators that regulatemechanical pain hypersensitivity do not elicit significant
effect on heat pain hypersensitivity, including toll-like
receptor-4 [19], myelin basic protein [17], IL-17 [13], IL-4
[18], and FN [20]. We have proposed that proteolytic
release of the cryptic myelin auto-antigens initiates mech-
anical allodynia by selectively engaging mechanosensory
myelinated A-afferents [17], involved in transducing the
force of innocuous, low-threshold touch stimulation into
nociceptive signal and the subsequent generation of
mechanical allodynia after nerve injury [21, 22, 46–50].
The present study established that the alternatively spliced
FN-CS1 isoform contributed to the selective mechanical
allodynia onset in a rodent neuropathy model by regulat-
ing a content of IL-17A-expressing (presumably, Th17)
cells at the nerve injury site.
Th17 cells (named after the cytokine IL-17 which they
produce) are believed to be important in pain after nerve
trauma [10, 13]. Although the IL-17A expression is gener-
ally restricted to a subtype of activated Th17 cells [51],
including that in the CCI nerve [10, 13], the possibility of
other endoneurial IL-17A+ cells in the post-CCI nerve
cannot be excluded. The overall impediment of T cell
function, achieved by the deletion of the CD4 gene [14] or
recombinant activating gene-1 [10, 16] or by depletion in
T cell production in athymic nude rats [9], improves
resistance to both thermal and mechanical pain hypersen-
sitivity. Thus, we suggest that the release of myelin auto-
antigens initiates Th17 cell polarization and homing to
myelinated afferents [17]. Subsequently, FN-CS1 mediates
T cell adhesion, migration, and rolling along myelinated
Fig. 3 Acute CS1 therapy reduces IL-17A levels in CCI nerve.
a Taqman qRT-PCR of IL-17A in sciatic nerve after acute intraneural
CS1 or sCS1 treatment (50 μg/ml in 5 μl) performed at day 7
post-CCI after the completion of behavioral testing (Fig. 2). The
mean relative mRNA ± SEM of n = 5/group normalized to GAPDH
compared to naive nerve (*p < 0.05). b Methylene blue/azure II
staining in 1-μm-thick sciatic nerve sections after acute intraneural
CS1 or sCS1 treatment (50 μg/ml in 5 μl) performed at day 7
post-CCI, after the completion of behavioral testing (Fig. 2). Control
nerve showed intact nerve morphology. CCI nerves displayed
Wallerian degeneration (axonal degeneration, edema, myelin ovoids,
and immune cell infiltration) after sCS1 treatment. In contrast, a
greater number of uncompromised axons were observed in CCI
nerves treated with CS1. Representative micrographs of n = 3/group.
Scale bars, 20 μm
Fig. 4 CS1 peptide inhibits Schwann cell activation. ERK1/2
immunoblotting in cultured Schwann cell lysates (11 μg total
protein each) treated with CS1. Schwann cells were either starved in
DMEM-1 % FBS for 24 h (a) or pre-treated with LPS (100 ng/ml) for
15 min (b) followed by CS1 (2.5 μg/ml) for 15 min or 1 h. The mean
optical density of pERK1/2 to total ERK1/2 ratio based on four
independent experiments (the graph, *p < 0.05)
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IL-17A [13] helps sustain the adaptive immune response
and the persistent state of mechanical allodynia. At the
later stage post-nerve damage, IL-17A release from Th17
cells may help sustain mechanical hypersensitivity by im-
peding Schwann-cell-mediated remyelination of sensory
neurons [55].
In the injured peripheral nerve, the Schwann cell was
the dominant source of FN-CS1, and interference with
FN-CS1/α4β1 integrin interactions using the synthetic
CS1 peptide repressed Schwann cell activation. Given that
by interference with FN-CS1/α4β1 integrin interactions
the CS1 peptide inhibited T cell homing, migration, and
proliferation [25–28, 52–54], and that Schwann cell
activation is central to immune cell recruitment into the
injury site [8, 56], we suggest that upon Schwann cell
activation, FN-CS1/α4β1 integrin binding (i) on endothe-
lial cells facilitates T cell homing and transmigration
across the blood-nerve barrier to the injured nerve and (ii)on Schwann cell basement membrane facilitates T cell
adhesion, migration, and rolling along myelinated fibers.
This latter mechanism offers the intriguing possibility of
T cell rolling along the injured neuroaxis to the dorsal
root ganglia and beyond. The present study does not dis-
tinguish myelinated efferent from afferent fibers within
the mixed (motor/sensory) sciatic nerve. However, noci-
ceptive factors released from the damaged efferents con-
tribute to mechanical pain hypersensitivity [57]. We did
not rule out the FN-CS1 deposition on Schwann cell
basement membrane of unmyelinated afferent C-fibers.
Within each Schwann cell basement membrane lie a bun-
dle of 2–10 unmyelinated C-fibers (Remak bundle), yet only
one A-fiber [30], suggesting more limited T cell access to
individual heat-sensitive C-fibers compared with mechano-
sensitive A-fibers. Notably, FN-CS1 also deposited on the
Schwann cell basement membrane immediately outside of
the nodes of Ranvier, the site of the likely T cell contact
post-CCI [17].
The sustained effect of the acute and local CS1 therapy
to attenuate mechanical but not thermal pain hypersensitiv-
ity has also been observed after the acute and local (intra-
spinal cord) CS1 injection after spinal cord dorsal column
hemisection [20]. This analgesic CS1 effect sustained over a
long (25-week) observation period and related to the
reduced serotonin 5-HT system and monocyte content in
the damaged spinal cord [20], although the changes in
adaptive immune response remain to be assessed in that
model. In addition to these localized effects to activate
Schwann cells and recruit immune cells into the injury site,
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gated ion channel P2X4 purino-receptor on spinal micro-
glia after spinal nerve injury [58]. However, when consider-
ing targeting the FN-CS1/α4β1 integrin binding by using
CS1 peptide or other approaches (e.g., α4 integrin-
neutralizing antibody, natalizumab) for neuropathy man-
agement [59], adverse effects on immune cell function or
Schwann-cell-mediated outgrowth of sensory neurons ex-
pressing α4β1 integrin [60, 61] should be assessed with
caution.
In the injured peripheral nerve, FN undergoes structural
modifications by the complete or partial inclusion or
exclusion of the alternatively spliced type IIICS/V domain
[31, 32]. V120, V95, and V0 splice forms of FN [42] and
(Fig. 1a) exist in both naïve and injured nerves [31, 32, 43],
with about a 20–50 % increase in the CS1-containing V120
following injury [60]. The levels of high molecular weight
FN species escalated day 7 post-CCI, the time of active T
cell recruitment [4, 9, 10, 12]. Proteolysis of FN by matrix
metalloproteinases (MMP)-9 and MMP-14 (Additional file
1: Figure S1), whose activity is significantly enhanced in
nerve injury [17, 56, 62], may contribute to the additional
molecular diversity of FN. The Leu-Asp-Val (LDV) se-
quence that is present in the nerve FN-CS1 binds α4β1 in-
tegrin on T cells with 20-fold more efficiency relative to the
Arg-Gly-Asp (RGD) sequence [42]. In addition to challen-
ging the FN-CS1/α4β1 integrin binding, the CS1 peptide
may act by interfering with α4β1 integrin interactions with
other ligands, such as vascular cell adhesion protein 1
[27, 63].
Conclusion
Expression of the FN-CS1 splice variant in peripheral nerve
was observed in a painful rodent neuropathy model. FN-
CS1, an extracellular glycoprotein, deposited into the
blood-nerve barrier and the Schwann cell basement mem-
brane underlying myelinated mechanosensory A-afferents.
Interference with the FN-CS1/α4β1 integrin interaction
using CS1 peptide therapy reduced the levels of the algesic
IL-17A and rescued the animals from the nerve-injury-
induced mechanical pain hypersensitivity.Additional file
Additional file 1: Figure S1. Prediction and ranking of the MMP
cleavage sites. The CS-1 region of the fibronectin peptide sequence.
The CS-1 sequence is present within the FN-CS1 splice variant. The
arrows point to the P1 residues of the putative cleavage sites. The data
suggest the presence of the multiple MMP cleavage sites in the CS-1
sequence including the cleavage site for MT1-MMP/MMP-14 (LPHP-NLH
and GPEI-LDV).
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